Registry following adults with hypertrophic cardiomyopathy across Austrian clinics
Collects health records from people with hypertrophic cardiomyopathy, a heart thickening condition, at Austrian clinics.
Key facts
- Who runs it
- Medical University of Graz
- Where
- Braunau am Inn, Graz, Innsbruck, Linz, Salzburg, Sankt Johann in Tirol, Sankt Pölten, Schwarzach im Pongau, Vienna, Wels-Grieskirchen, and Wiener Neustadt, AustriaSee the 15 sites
- Trial code
- Registry title
- Austrian Hypertrophic Cardiomyopathy Registry
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 8 Mar 2024
- Expected to end
- Mar 2044
- Type of study
- Observational
- Record updated
- 5 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hypertrophic cardiomyopathy who attend a heart muscle clinic at a taking-part centre in Austria, and who have a clearly thickened wall between the heart chambers.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Hypertrophic cardiomyopathy with a thickened wall between the heart chambers (interventricular septum): 13 mm or more with cardiomyopathy-specific red flags, or 15 mm or more not explained by loading conditions, or 17 mm or more.
Main reasons for not taking part
- Younger than 18 years
- Known cardiac amyloidosis
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
- Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
- Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures
Who cannot take part
- Known cardiac amyloidosis
- Age < 18 years
Where in Austria
- Hospital St. Josef BraunauBraunau am Inn, AustriaContact: Johann Auer, MDTaking people
- Hospital Graz 2 WestGraz, AustriaContact: Gert Waltl, MDTaking people
- Medical University of GrazGraz, AustriaContact: Nicolas D Verheyen, MDTaking people
- Medical University of InnsbruckInnsbruck, AustriaContact: Marc-Michael Zaruba, MDTaking people
- Kepler University Hospital LinzLinz, AustriaContact: Christian Reiter, MDTaking people
- Ordensklinikum LinzLinz, AustriaContact: Christian Ebner, MDTaking people
- Paracelsus Medical University of SalzburgSalzburg, AustriaContact: Christina Granitz, MDTaking people
- General Hospital St. Johann in TirolSankt Johann in Tirol, AustriaContact: Peter P Rainer, MDTaking people
- University Hospital St. PöltenSankt Pölten, AustriaContact: Deddo Mörtl, MDTaking people
- Clinic Cardinal SchwarzenbergSchwarzach im Pongau, AustriaContact: Anna Rab, MDTaking people
- Klinik OttakringVienna, AustriaContact: Stephan Dobner, MDTaking people
- Medical University of ViennaVienna, AustriaContact: Daniel Dalos, MDTaking people
- Favoriten Clinic ViennaVienna, AustriaContact: Nicolas D Verheyen, MDNo longer taking part
- Clinic Wels-GrieskirchenWels-Grieskirchen, AustriaContact: Thomas Weber, MDTaking people
- Hospital Landesklinikum Wiener NeustadtWiener Neustadt, AustriaContact: Martin Grübler, MDTaking people
About the trial
What the trial wants to find out
The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Austrian Hypertrophic Cardiomyopathy Registry
- Plain-language title
- Registry following adults with hypertrophic cardiomyopathy across Austrian clinicsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 5 December 2025